Imada K — Endo Lab

article 2025

Novel screening approach for stem cell selective inhibitors and their possible translational therapeutic potential for endometriosis

Reproductive biology ·doi:10.1016/j.repbio.2024.100992

Endometriosis is an estrogen-dependent benign disease characterized by growth of the endometrial tissue outside the uterine wall. Several reports suggest the possibility of the pathogenesis and recurrence of endometriosis being related to f…

article 2014

Dienogest, a synthetic progestin, down-regulates expression of CYP19A1 and inflammatory and neuroangiogenesis factors through progesterone receptor isoforms A and B in endometriotic cells

The Journal of steroid biochemistry and molecular biology ·doi:10.1016/j.jsbmb.2014.12.008

Dienogest (DNG) is a selective progesterone receptor (PR) agonist and oral administration of DNG is used for the treatment of endometriosis. DNG is considered to act on PR to down-regulate pathophysiological factors associated with endometr…

article 2013

Dienogest inhibits nerve growth factor expression induced by tumor necrosis factor-α or interleukin-1β

Fertility and sterility ·doi:10.1016/j.fertnstert.2013.10.038

ObjectiveDienogest (DNG), a selective P receptor (PR) agonist, is used to treat endometriosis. To investigate whether DNG affects nerve growth factor (NGF) expression, we stimulated human endometrial epithelial cells (hEECs) with inflammato…

2009

[Pharmacological and clinical profile of dienogest (DINAGEST Tab. 1 mg)].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica ·doi:10.1254/fpj.133.32